CVI Holdings LLC raised its position in Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) by 155.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 184,667 shares of the biotechnology company’s stock after acquiring an additional 112,452 shares during the period. Invivo Therapeutics makes up approximately 0.6% of CVI Holdings LLC’s holdings, making the stock its 16th biggest holding. CVI Holdings LLC’s holdings in Invivo Therapeutics were worth $279,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NVIV. Renaissance Technologies LLC boosted its stake in Invivo Therapeutics by 90.3% in the third quarter. Renaissance Technologies LLC now owns 236,672 shares of the biotechnology company’s stock valued at $478,000 after acquiring an additional 112,300 shares in the last quarter. Vanguard Group Inc boosted its stake in Invivo Therapeutics by 358.4% in the third quarter. Vanguard Group Inc now owns 86,088 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 67,307 shares in the last quarter. Vanguard Group Inc. boosted its stake in Invivo Therapeutics by 358.4% in the third quarter. Vanguard Group Inc. now owns 86,088 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 67,307 shares in the last quarter. Finally, IMS Capital Management boosted its stake in Invivo Therapeutics by 27.4% in the third quarter. IMS Capital Management now owns 31,754 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 6,838 shares in the last quarter. Institutional investors own 8.15% of the company’s stock.

Separately, ValuEngine upgraded shares of Invivo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 2nd.

Shares of NVIV opened at $1.58 on Friday. The company has a market capitalization of $14.62 million, a price-to-earnings ratio of -0.09 and a beta of 1.71. Invivo Therapeutics Holdings Corp has a twelve month low of $1.34 and a twelve month high of $17.00.

TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2019/03/17/invivo-therapeutics-holdings-corp-nviv-holdings-raised-by-cvi-holdings-llc.html.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.

Recommended Story: Cost of Equity For A Business, Investors

Want to see what other hedge funds are holding NVIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invivo Therapeutics Holdings Corp (NASDAQ:NVIV).

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.